SquamousCellCarcinomaofSkin near Teaneck, NJ

Biography: Dr. Barbara T. Ma, is an Assistant Professor of Medicine at Weill Cornell Medicine and an Assistant Attending Physician at New York Presbyterian Hospital. Dr. Ma graduated with B.S. in Biomedical Engineering and M.S. in Biotechnology from Johns Hopkins University. She received her medical degree from New York Medical College. She completed her internal medicine training at Georgetown University Hospital and fellowship in Hematology/Oncology at NewYork-Presbyterian Hospital/Weill Cornell Medicine, where she also served as a chief fellow. Dr. Ma cares for patients with skin cancers, including melanoma. Her research focus is optimizing immunotherapy treatments for solid tumor patients with special interest on immunotherapy toxicities. She heads the Phase I unit and leads Cellular Therapy for Solid Tumors at Cornell. Dr. Ma is a recipient of the American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award. She is a member of American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), Golden Humanism Honor Society (GHHS), and Society for Immunotherapy and Translational Research in Cancer.

Care Philosophy: I treat every patient as a valued member of my family. My mission is to provide my patients with quality medical care and an exceptional healthcare experience.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Biography: Dr. Monica Hayes, MD is an Oncology Specialist who practices in New York, NY. She is 54 years old and has been practicing for 28 years. Dr. Monica Hayes, MD is affiliated with Mount Sinai Queens, Mount Sinai Brooklyn and Mount Sinai Morningside.

Care Philosophy: At Moffitt Cancer Center, we are working tirelessly in the areas of patient care, research and education to advance one step further in fighting cancer. As a National Cancer Institute-designated Comprehensive Cancer Center, we are committed to the health and safety of our patients and dedicated to providing expert cancer care. From enhanced quality of life to complete remission, Moffitt is Florida's top choice aiming to achieve the best outcome for each patient.

Biography: Dr. Feldman is an Assistant Professor of Medicine in the Division of Cardiology of the Department of Medicine at Weill Cornell Medical College and an Attending Physician at New York Presbyterian-Weill Cornell Medical Center.Dr. Feldman grew up in Framingham, Massachusetts and completed her undergraduate studies at the University of Pennsylvania. She earned her medical degree from Boston University School of Medicine, completed Internal Medicine residency at Beth Israel Deaconess Medical Center/Harvard Medical School, where she completed the Clinician Educator Track, fellowship in Cardiovascular Disease at Boston Medical Center/Boston University School of Medicine, and an additional fellowship in Cardio-Oncology at Memorial Sloan Kettering Cancer Center. After training, she founded and directed the Cardio-Oncology and Cardiac Amyloidosis programs at Rutgers New Jersey Medical School/University Hospital. In 2023, she joined the Cardiology Division at New York-Presbyterian/Weill Cornell Medical College as a full-time faculty member where she provides expertise in cardio-oncology, cardiac imaging, and medical education. She serves as the Director of the Cardio-Oncology program.Dr. Feldman is board certified in Internal Medicine, Cardiovascular Diseases, Echocardiography, Nuclear Cardiology, and Cardio-Oncology. She is a fellow of the American College of Cardiology, and a member of the American Heart Association, American Society of Nuclear Cardiology, and the International Society of Cardio-Oncology.

Care Philosophy: I realize how scary it can be to receive a life-threatening diagnosis, and firmly believe in taking the time to clearly communicate with my patients about the nature of their disease and their various treatment options. This can not only vastly improve our patients' experiences, but also their treatment outcomes, as an educated patient is able to make informed decisions about care and reclaim some of the autonomy that can be lost when coping with a cancer diagnosis. In the midst of all the cutting-edge science and technology that we offer, I find it extremely important to remember that it is the patient who is the center of it all. I genuinely care about my patients, and instilling a sense of hope, sharing a laugh, or a kind word can be as important as all the medical advances and state-of-the-art science.

Biography: Dr. Cora Sternberg is a leading international researcher and world expert in the field of medical oncology, genitourinary (GU) cancers, and drug development. As a key opinion leader in three different types of genitourinary cancers, Dr. Sternberg isknown for her influential work in developing novel therapies and targeted agents for the treatment of prostate, renal and bladder cancers.Dr. Sternberg helped develop the original M-VAC chemotherapy regimen, as well as the double-dose/high-dose/accelerated-dose M-VAC chemotherapy regimens in bladder and urothelial cancers. These treatments are the gold standard, saving many lives and decreasing suffering in patientswith these diseases.Additionally, Dr. Sternberg has served as principal investigator or been involved in numerous practice-changing studies for prostate cancer. These research efforts have led to the FDA approvals of abiraterone acetate and enzalutamide in advanced prostate cancer. Most recently, her publication in the New England Journal of Medicine (NEJM) demonstrated dramatic improvements in metastasis-free survival (MFS) in men with castration resistant prostate cancer (CRPC) without evidence of metastatic disease, but at high risk of developing metastases, a population for whom there were previously no approved therapeutics. This research led to the approval of enzalutamide in the M0 CRPC patient population.Dr. Sternberg has been instrumental in the development of the drug Pazopanib, an antiangiogenic targeted therapy, for advanced clear cell renal cell carcinoma. Dr. Sternberg served as lead investigator in the large phase 3 international study that demonstrated the efficacy, safety and tolerability of this drug in patients with metastatic kidney cancer, culminating in the FDA approval. She has also participated in the development of other antiagiogenic agents such as sunitinib, cabozantinib, tivozanib and dovitinib to treat renal cell cancer.At Weill Cornell Medicine and NewYork-Presbyterian Hospital, Dr. Sternberg will facilitate the continued growth and development of clinical and translational research programs in genitourinary (GU) malignancies, with a particular emphasis on expanding the breadth and depth of clinical and translational research. AsClinical Director of the Englander Institute for Precision Medicine (EIPM), Dr. Sternberg will develop strategies to incorporate genomic sequencing and precision medicine throughout the Weill Cornell Medicine and NewYork-Presbyterian healthcare network, including Lower Manhattan, Brooklyn and Queens. In addition to providing her clinical and research expertise in genitourinary oncology, Dr. Sternberg will work closely with Olivier Elemento, PhD, renowned computational biologist and Director of the EIPM, to develop novel strategies and apply precision oncology to optimize cancer prevention, detection and treatment across a variety of tumor types.Dr. Sternberg previously served as Chief of the Department of Medical Oncology at the San Camillo-Forlanini Hospital in Rome, Italy, and adjunct Professor of Oncology at La Sapienza University in Rome. A graduate of the University of Pennsylvania undergraduate and medical schools, Dr. Sternberg completed her fellowship and previously was on staff at Memorial Sloan Kettering Cancer Center.Dr. Sternberg has published approximately 400 articles in peer-reviewed publications,including more than 100 first-authored articles. She has co-edited six textbooks, guest edited six others, and has published over 80 book chapters. Dr. Sternberg has lectured extensively at universities and cancer symposia worldwide, having given approximately 750 invited talks atprestigious international venues.Throughout her career, she has served on the editorial boards of Critical Reviews in Hematology and Oncology, Annals of Oncology, and the Journal of Clinical Oncology, and she currently serves on the editorial boards of Oncology, European Urology, the Harvard Medical School Annual Report on Prostate Diseases, Kidney Cancer, Nature Clinical Practice Urology, and European Urology Oncology. Dr. Sternberg also serves as Reviewer for the New England Journal of Medicine, the Journal of Clinical Oncology, the Lancet Oncology and others.She currently serves as the Solid Tumor Editor for Critical Reviews in Hematology and Oncology, Section Editor for Urologic Oncology, Associate Editor for Bladder Cancer Clinical Trials Corner, Associate Editor and Genitourinary Oncology Editor for ESMO Open-Cancer Horizons, and Associate Editor for Frontiers in Oncology. Additionally, Dr. Sternberg previously served as Oncology Editor for the British Journal of Urology, Section Editor for Urologic Oncology, and Genitourinary Editor for the European Journal of Cancer.Dr. Sternberg's leadership in the field is further exemplified by the numerous international committees on which she has served. She was elected to three consecutive terms as Board Member and Executive Board Member of the European Organization for Research and Treatment of Cancer (EORTC) and elected to the nominating committee of the American Society of Clinical Oncology (ASCO) board of directors, currently serving a 3-year term.This document has been edited with the instant web content composer which can be found at htmleditor.tools - give it a try.